ql-007
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 20, 2017 (NCT03244085)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04157257 | Phase 2 | Jul 26, 2019 | Jilin University, Qilu Pharmaceutical Co., Ltd., Southern Medical University |
| NCT04157699 | Phase 2 | Jul 26, 2019 | Jilin University, Qilu Pharmaceutical Co., Ltd., Southern Medical University |
| NCT03770624 | Phase 1 | Oct 16, 2018 | Qilu Pharmaceutical Co., Ltd. |
| NCT03244085 | Phase 1 | Aug 20, 2017 | Qilu Pharmaceutical Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 4 | 4 | 2 | 2017 |
| Jilin University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Southern Medical University | Academic/Hospital | 2 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1